葵花药业(002737) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥1,216,722,019.77, representing a 33.70% increase compared to ¥910,027,853.40 in the same period last year[9]. - Net profit attributable to shareholders was ¥225,869,003.12, up 46.53% from ¥154,143,953.63 year-on-year[9]. - The net profit after deducting non-recurring gains and losses was ¥215,120,160.37, reflecting a 47.32% increase from ¥146,023,980.47 in the previous year[9]. - The basic earnings per share increased to ¥0.39, a rise of 44.44% compared to ¥0.27 in the same period last year[9]. - Total operating revenue for the current period reached CNY 1,216,722,019.77, a significant increase from CNY 910,027,853.40 in the previous period, representing a growth of approximately 33.6%[75]. - Total operating costs amounted to CNY 906,568,193.56, up from CNY 710,432,872.34, indicating an increase of about 27.6%[78]. - Net profit for the current period was CNY 243,082,530.17, compared to CNY 161,002,031.79 in the previous period, reflecting a growth of approximately 50.9%[81]. - Total comprehensive income attributable to the parent company was CNY 225,888,266.00, up from CNY 154,353,763.23 in the previous period, representing an increase of approximately 46.3%[85]. - Basic and diluted earnings per share both increased to CNY 0.39 from CNY 0.27, reflecting a growth of 44.4%[85]. Cash Flow - The net cash flow from operating activities was ¥220,961,896.05, down 10.89% from ¥247,958,852.87 year-on-year[9]. - The net cash flow from investment activities was -¥8,108.26 million, a decrease of 145.70% compared to -¥3,300.02 million in the previous period, mainly due to cash outflow for purchasing financial products[24]. - The company’s cash flow from financing activities showed a drastic decline of -1040.96%, from ¥1,844.39 million to -¥17,354.93 million, primarily due to a decrease in cash inflow from financing activities[24]. - The net cash flow from financing activities was -173,549,308.13, compared to 18,443,850.63 in the previous period, indicating a significant decrease in financing cash flow[99]. - The cash flow from investment activities showed a net outflow of -52,360,337.90, contrasting with a net inflow of 107,333,449.10 in the previous period, indicating a shift in investment cash flow dynamics[103]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,114,662,089.14, a slight increase of 0.03% from ¥5,113,343,143.57 at the end of the previous year[9]. - The company's current assets totaled CNY 2,923,777,259.19, compared to CNY 2,937,267,451.04 at the end of 2020, indicating a decrease of approximately 0.46%[57]. - Total liabilities decreased to CNY 1,481,736,167.69 from CNY 1,722,583,177.34, marking a reduction of about 14.00%[63]. - The company's total assets decreased to CNY 3,247,711,243.45 from CNY 3,439,290,879.02, a decline of about 5.6%[73]. - Total liabilities decreased to CNY 1,024,153,277.37 from CNY 1,216,175,578.37, representing a reduction of approximately 15.8%[73]. - The company's equity attributable to shareholders rose to CNY 3,405,265,016.64 from CNY 3,180,232,064.90, an increase of approximately 7.06%[66]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 52,748[14]. - The company repurchased a total of 3,838,503 shares during the reporting period, accounting for 0.66% of the total share capital, with a total expenditure of ¥56.33 million[28]. - The company has committed to repurchase all newly issued shares if there are false records or misleading statements in the prospectus, with the repurchase price not lower than the issuance price plus interest from the listing date to the repurchase offer date[34]. - The commitment to repurchase shares must be executed within 30 trading days after the shareholders' meeting approval, with a repurchase price based on the higher of the issuance price plus interest or the average weighted price over the last 30 trading days prior to the regulatory investigation[34]. - The company has a long-term commitment to compensate investors for losses incurred due to false records or misleading statements in the prospectus[34]. Government and Regulatory Compliance - The company received government subsidies amounting to ¥50,453,813.28 during the reporting period[9]. - The company has ongoing commitments to ensure compliance with legal regulations regarding share repurchase and investor compensation[34]. - The company will actively take legal measures to fulfill its commitments regarding the issuance and listing of shares, accepting supervision from regulatory authorities and investors[34]. - The company has not experienced any non-operational fund occupation by controlling shareholders during the reporting period[49]. Operational Insights - The company has engaged in multiple investor communications regarding financial data and operational performance throughout January 2021[50]. - The company has plans for future market expansion and product development, although specific details were not disclosed in the report[66]. - The company has implemented new leasing standards effective from January 1, 2021, which may impact future financial reporting[114].